Literature DB >> 25658260

Antidotes progress for new oral clotbusters.

Elie Dolgin.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25658260     DOI： 10.1038/nbt0215-117

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Antithrombotic drugs market.

Authors:  Kritika Chaudhari; Bashar Hamad; Basharut A Syed
Journal:  Nat Rev Drug Discov       Date:  2014-07-04       Impact factor: 84.694

2.  Use of PER977 to reverse the anticoagulant effect of edoxaban.

Authors:  Jack E Ansell; Sasha H Bakhru; Bryan E Laulicht; Solomon S Steiner; Michael Grosso; Karen Brown; Victor Dishy; Robert J Noveck; James C Costin
Journal:  N Engl J Med       Date:  2014-11-05       Impact factor: 91.245
  2 in total
  3 in total

Review 1.  Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.

Authors:  Kamrouz Ghadimi; Jerrold H Levy; Ian J Welsby
Journal:  Anesth Analg       Date:  2016-05       Impact factor: 5.108

2.  Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling.

Authors:  J Almquist; M Penney; S Pehrsson; A-S Sandinge; A Janefeldt; S Maqbool; S Madalli; J Goodman; S Nylander; P Gennemark
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-06-16

3.  Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452.

Authors:  Ann-Sofie Sandinge; Annika Janefeldt; Susanne Pehrsson; Sven Nylander
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.